Ventyx Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTYX and other ETFs, options, and stocks.About VTYX
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
CEORaju S. Mohan
CEORaju S. Mohan
Employees82
Employees82
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2018
Founded2018
Employees82
Employees82
VTYX Key Statistics
Market cap129.51M
Market cap129.51M
Price-Earnings ratio-1.04
Price-Earnings ratio-1.04
Dividend yield—
Dividend yield—
Average volume1.94M
Average volume1.94M
High today$1.99
High today$1.99
Low today$1.61
Low today$1.61
Open price$1.75
Open price$1.75
Volume8.01M
Volume8.01M
52 Week high$5.66
52 Week high$5.66
52 Week low$0.783
52 Week low$0.783
Analyst ratings
67%
of 9 ratingsBuy
66.7%
Hold
33.3%
Sell
0%
People also own
Based on the portfolios of people who own VTYX. This list is generated using Robinhood data, and it’s not a recommendation.